Myasthenia gravis (MG) is an autoimmune neuromuscular junction disorder characterised by fatigable weakness -- weakness that worsens with activity and improves with rest. It is caused by autoantibodies against acetylcholine receptors (AChR antibodies, 85% of cases) or muscle-specific kinase (MuSK antibodies, 6-8%). The hallmark of MG is fluctuation: patients can be near-normal first thing in the morning (after overnight rest) and severely weak by afternoon. This fluctuation profoundly affects walking cane use -- the cane need changes through the day and from day to day.
MG Features That Affect Gait
- Proximal leg weakness: hip flexors and knee extensors are often affected; ascending stairs and rising from chairs are disproportionately impaired; Gowers manoeuvre (using arms to rise from floor) may be needed
- Fatigable weakness: the first few steps may be nearly normal; after 50-100m, the legs fatigue rapidly and walking becomes increasingly difficult
- Respiratory involvement: in moderate-severe MG, respiratory muscle weakness reduces exertional capacity; walking causes breathlessness from respiratory fatigue, not cardiac or pulmonary disease
- Ptosis and diplopia: ocular involvement does not directly impair walking but diplopia can impair balance; a patch on one eye eliminates diplopia
- Bulbar involvement: swallowing and speech affected; does not directly impair walking but indicates more severe MG
Walking Cane for Myasthenia Gravis
A walking cane in MG is a fatigability management tool rather than a structural support:
- Reduces the metabolic and muscular cost of walking per step, extending the distance before muscle fatigue becomes limiting
- Provides support at the end of a walk when fatigue is maximal
- Most useful in the afternoon and evening when MG weakness is typically worst
- May not be needed in the morning when the patient is rested
MG Disease Severity and Walking Aid
| MG Severity (MGFA Class) | Walking Limitation | Walking Aid |
|---|---|---|
| MGFA Class I (ocular only) | No limb weakness; diplopia may affect balance | No cane typically; eyepatch for diplopia balance |
| MGFA Class IIA (mild generalised; predominantly limb) | Fatiguable weakness; can walk moderate distances | Cane for longer walks and afternoon use; not needed in morning |
| MGFA Class IIB (mild generalised; predominantly bulbar/respiratory) | Fatigue-limited walking; respiratory involvement | Cane; monitor respiratory function during walking |
| MGFA Class III-IV (moderate to severe) | Significant walking limitation; may need assistance | Cane or rollator; exacerbation monitoring; avoid overexertion |
| Myasthenic crisis | Respiratory failure; ICU level | No walking; acute management; cane irrelevant in crisis |
Pyridostigmine Timing and Cane Use
Pyridostigmine (acetylcholinesterase inhibitor) is the first-line symptomatic treatment for MG. It improves neuromuscular transmission but has a duration of action of 4-6 hours. Patients often time their pyridostigmine dose to peak at times when they need to walk (e.g., taking a dose 30 minutes before a planned walk). This pyridostigmine timing strategy may reduce cane need during the peak action window.
Explore DaiWalk walking canes. Related: Walking Cane for Inflammatory Myopathy | Walking Cane for ME/CFS.
